CHICAGO / Dec 02, 2025 / Business Wire / At the Radiological Society of North America (RSNA) 2025 Annual Meeting, GE HealthCare (Nasdaq: GEHC) is showcasing several innovations brought to life through an expanded collaboration with NVIDIA. This collaboration underscores GE HealthCare’s ongoing commitment to integrating advanced technologies that aim to transform healthcare delivery and improve patient care. The company is leveraging NVIDIA’s offerings and expertise in areas of physical AI, high performance computing, and simulation, which has the potential to reduce manual tasks, increase patient comfort, and alleviate radiologist burnout through AI-powered assistance.
GE HealthCare and NVIDIA are working together to address some of the most pressing challenges in medical imaging and diagnostics with solutions that aim to shorten scan times, enhance diagnostic clarity, and improve clinical workflows. This is especially urgent given that approximately 30% of the world’s data is generated by the healthcare industry5, yet healthcare systems only use about 3% of it due to fragmented systems and inefficient workflows.6 As highlighted at RSNA this year, this collaboration is powering next-generation solutions across modalities—from CT and PET, to cardiac, mammography, and ultrasound systems—by integrating NVIDIA’s full-stack accelerated computing platforms to process large, complex datasets with speed and precision.
“We are redefining diagnostic imaging by fusing GE HealthCare’s deep clinical expertise and imaging innovation with NVIDIA’s edge AI and accelerated computing platforms,” said Roland Rott, President and CEO, Imaging, GE HealthCare. “With co-development efforts spanning simulation, segmentation, and real-time image reconstruction, and a joint go-to-market strategy underway, this alliance enables us to drive scalable innovation across the continuum of care. Together, we are creating a future of smarter, faster, and more autonomous imaging workflows.”
“A future where medical imaging devices are intelligent and robotic has the potential to expand the scale and reach of diagnostic imaging to more places and more patients than ever before,” said Kimberly Powell, Vice President of Healthcare at NVIDIA. “Together with GE HealthCare, we’re reimagining how imaging systems are built, deployed, and enhanced—in order to create smarter scans and faster workflows which could improve diagnoses and treatments for patients globally.”
Key GE HealthCare innovations leveraging NVIDIA’s technology include:
Innovations unveiled at RSNA 2025 [510(k) pending at the U.S. FDA. Not available for sale.]:
Concepts in development
In March, GE HealthCare and NVIDIA announced their intent to explore autonomous X-ray and autonomous ultrasound solutions aiming to bring even greater efficiencies to healthcare providers. This autonomous imaging initiative aims to leverage NVIDIA Isaac™ for Healthcare—an AI robotics development platform tailored for medical environments—together with NVIDIA Holoscan, a real-time edge AI computing platform designed for autonomous ultrasound systems. The future goal is for these capabilities to be deployed at the edge, close to existing medical devices, on a range of NVIDIA hardware platforms to help automate parts of the workflow. The autonomous vision is to streamline workflows by helping accelerate diagnostic turnaround, which can support expanding access to care to underserved areas. At RSNA 2025, GE HealthCare will seek feedback for potential concepts that incorporate autonomous x-ray and ultrasound technology through limited, early-stage exploratory demonstrations.12
“We’re proud to be strengthening our long-standing relationship with NVIDIA and to make meaningful strides toward the future of intelligent imaging,” said Philip Rackliffe, President and CEO, Advanced Visualization Solutions, GE HealthCare. “By integrating NVIDIA’s full-stack platform, we’re advancing the technologies needed for autonomous X-ray and ultrasound imaging. These innovations in development bring us closer to scalable, AI-powered imaging that supports clinicians, aims to improve patient outcomes, and helps expand access to high-quality care with speed and efficiency.”
1 Photonova Spectra is 510(k)-pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other region. | |
2 SIGNA Sprint with Freelium is a configuration of SIGNA Sprint Select. SIGNA Sprint Select is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale. | |
3 SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale. | |
4 Concept only. May never become a product. Not for Sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability. | |
5 RBC Capital Markets. (n.d.). The healthcare data explosion. RBC Capital Markets. https://www.rbccm.com/en/gib/healthcare/episode/the_healthcare_data_explosion | |
6 World Economic Forum. (2024, January 5). How to harness health data to improve patient outcomes. World Economic Forum. https://www.weforum.org/stories/2024/01/how-to-harness-health-data-to-improve-patient-outcomes-wef24/ | |
7 When compared to Revolution Apex Elite. | |
8 Photonova Spectra is 510(k)-pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other region. | |
9 SIGNA Sprint with Freelium is a configuration of SIGNA Sprint Select. SIGNA Sprint Select is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale. | |
10 Helium is permanently enclosed in the magnet. 1% helium compared to conventional magnets. | |
11 SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale. | |
12 Concept only. May never become a product. Not for Sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability. | |
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
| Last Trade: | US$83.59 |
| Daily Change: | 3.37 4.20 |
| Daily Volume: | 4,779,563 |
| Market Cap: | US$38.080B |
December 03, 2025 December 03, 2025 December 01, 2025 November 30, 2025 November 30, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load